Immunophotonics, Inc.
St. Louis, US · Founded 2012 · Delaware corporation · 18 employees on LinkedIn · 4 known investors
Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.
Founders & leadership
DH
Dr. HodeCo-Founder & Senior Fellow
MA
Mr. AlleruzzoCo-Founder & Director
DC
Dr. ChenCo-Founder
DR
Dr. Robert NordquistCo-Founder
LA
Luciano AlleruzzoCo-founder
WC
Wei ChenCo-founder
AM
Alexander Michael HurstExecutive
RH
Robert H. ArchinPresident & Chief Executive Officer
Board
DS
BS
MM
Miguel M. ZubizarretaBoard director
CB
Charlie BoltenBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$17.6M disclosed across 4 rounds · 2014–2025
▶$10.1MraisedSep 2026 · 45 investors · PharmaceuticalsRule 506(b)
▶$10.1MraisedSep 2026 · 45 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Alexander Michael HurstExecutive Officer
- Robert H. ArchExecutive Officer
- Miguel M. ZubizarretaDirector
- Luciano AlleruzzoDirector, Promoter
- Jonathan KnowlesDirector
- Wei ChenDirector, Promoter
- Jacqueline HessDirector
- Richard LevensonDirector
- Amount sold
- $10.1M
- Minimum investment
- $100K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2024 · 17 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMar 2024 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bobby W. SandageDirector
- Wei R. ChenDirector, Promoter
- Miguel ZubizarretaDirector
- Charlie BoltenDirector
- Tomas HodeExecutive Officer, Director, Promoter
- Jonathan KnowlesDirector
- Luciano AlleruzzoExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $1.5M
- Minimum investment
- $25K
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b
▶$3.5MraisedFeb 2023 · 22 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedFeb 2023 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Luciano AlleruzzoExecutive Officer, Director, Promoter
- Tomas HodeExecutive Officer, Director, Promoter
- Jonathan KnowlesDirector
- Miguel ZubizarretaDirector
- Charlie BoltenDirector
- Wei R. ChenDirector, Promoter
- Bobby W. SandageDirector
- Offering amount
- $6.5M
- Amount sold
- $3.5M
- Minimum investment
- $50K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b
▶$2.5MraisedJan 2015 · 28 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJan 2015 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SmollerDirector
- Charlie BoltenDirector
- Tomas HodeExecutive Officer, Director
- Bobby SandageDirector
- Robert E. NordquistDirector
- Lu AlleruzzoExecutive Officer
- Wei R. ChenDirector
- Peter A. JenkinsDirector
- Offering amount
- $3.4M
- Amount sold
- $2.5M
- First sale
- Jun 2014
- Incorporated
- Corporation, Wyoming, 2012
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld11 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Immunomic Therapeutics9 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Companies competing with Immunophotonics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $400K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immunophotonics, Inc. do?
- Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.
- Who founded Immunophotonics, Inc.?
- Immunophotonics, Inc. was founded by Dr. Hode, Mr. Alleruzzo, Dr. Chen, Dr. Robert Nordquist, Luciano Alleruzzo, Wei Chen in 2012.
- Who are Immunophotonics, Inc.'s investors?
- Immunophotonics, Inc.'s investors include BioGenerator Ventures, iSelect Fund, Missouri Technology Corporation, Cultivation Capital.
- How much funding has Immunophotonics, Inc. raised?
- Immunophotonics, Inc. has disclosed $17.6M raised across 4 rounds.
- Where is Immunophotonics, Inc. headquartered?
- Immunophotonics, Inc. is headquartered in St. Louis, US.